58M, newly diagnosed localized intermediate-risk prostate cancer on biopsy (Gleason 3+4), PSA 7.2, no nodal or distant spread on staging. Otherwise fit, no major comorbidities, active and working full-time. Urology has presented two options so far: radical prostatectomy or external-beam radiotherapy with short-course hormone therapy; active surveillance was mentioned once in passing but not discussed in detail. No documentation yet of what matters most to the patient (e.g. continence, sexual function, avoiding ongoing hospital visits). Decision has been framed as needing to be made "within the next few weeks."
What's actually being decided, is it urgent, whose decision is it, is a false binary being presented
**Case Note on Option Availability:** The case data presents two primary active treatment options (radical prostatectomy and external-beam radiotherapy with short-course hormone therapy), alongside active surveillance mentioned in passing; therefore, the case data does not present only one option. --- ### Domain 1: The Decision Itself **Clarifying What Is Being Decided** 1. What exactly am I being asked to decide right now—am I choosing a definitive treatment plan today, or am I just deciding on the next step in evaluating my options? 2. My urology team mentioned deciding within the next few weeks—is this decision genuinely urgent based on my Gleason 3+4 biopsy results and PSA of 7.2, or do I have time to pause, think, and gather more information? 3. Who is ultimately supposed to make this decision—is this my choice to make, a decision for me and my family, or a decision where the team tells me what I should do? 4. What specifically happens to my health, cancer risk, or long-term prognosis if I don't make a final decision within the next few weeks? 5. Active surveillance was mentioned once in passing—is "doing nothing for now" besides close monitoring
Full option list including doing nothing, side-by-side comparison across every option present
1. What are all the management options available for my specific localized intermediate-risk prostate cancer (Gleason 3+4, PSA 7.2), including active surveillance or watching and waiting? 2. Since active surveillance was mentioned briefly, can we discuss in detail whether taking a surveillance approach is a safe and reasonable option for my specific tumor characteristics, or if immediate active treatment is strongly recommended? 3. What would happen to my cancer and my health if I chose not to do any treatment or surveillance right now, or if I delayed making a decision beyond the next few weeks? 4. Are there non-surgical or non-pharmacological options, focal treatments, or clinical trials for intermediate-risk prostate cancer that exist elsewhere but aren't offered at this facility? 5. Would seeing a specialist at another center or consulting a radiation oncologist give me access to options or treatment approaches that we haven't discussed today? 6. For radical prostatectomy, what would my day-to-day life actually look like during recovery and over the long term, especially regarding my ability to work full-time and stay active? 7. For external-beam radiotherapy with short-course hormone therapy, what would my day-to-day life actually look like during and after the treatment schedule? 8. For active surveillance, what would my day-to-day life actually look like in terms of required monitoring, repeat testing, and ongoing appointments? 9. For each of these options—surgery, radiation with hormone therapy, and active surveillance—could you describe in plain terms what a "good outcome" and a "bad outcome" would look like for someone in my situation?
Specific/numeric benefit, harm and trade-off specificity, who has weighed gain vs. loss
**Domain 3: Benefits & Harms** 1. For each of the three options mentioned—radical prostatectomy, external-beam radiotherapy with short-course hormone therapy, or active surveillance—what specifically will get better in my health or life, and over what timeframe? 2. Out of 100 men like me (58 years old, fit, working full-time, with Gleason 3+4 localized prostate cancer and a PSA of 7.2), roughly how many are actually helped in terms of preventing cancer spread or cancer death by choosing surgery or radiation compared to active surveillance? 3. Is the benefit of treating my intermediate-risk cancer right now about helping me live longer, keeping me feeling good and symptom-free, or both—and which of those does each option actually deliver? 4. Beyond showing a low PSA number or clean scans on my follow-up tests, what does "success" mean for each option in terms I would actually notice in my daily life, work, and physical activity? 5. What are the most common side effects and complications for surgery versus radiation combined with short-course hormone therapy—specifically regarding urinary control, erectile function, and bowel habits—and out of 100 men like me, how many experience these issues long-term? 6. What are the specific short-term and lingering side effects of the short-course hormone therapy itself—such as fatigue, hot flashes, mood changes, or impacts on muscle mass—and how might these affect my ability to stay active and work full-time during treatment? 7. What is the worst realistic outcome or complication for each option, even if it is rare? 8. Are there specific harms, functional losses, or side effects—like scar tissue, urinary leaking, or radiation-induced bowel changes—that might not show up right away, but could only become clear months or years later? 9. Has the clinical team already weighed these specific benefits against the side effects and trade-offs for a man in my exact situation, or is that weighing process being left to me alone to figure out?
How confident anyone is, whether evidence applies to this patient, source and bias of the numbers
**Domain 4: Certainty & Evidence Quality** 1. How much solid evidence is there comparing surgery, radiation with short-course hormone therapy, and active surveillance for someone with my exact diagnosis (Gleason 3+4, PSA 7.2)? Is the guidance based on strong, long-term clinical trials or more on expert consensus for a case like mine? 2. Is there anything about my specific situation—being 58 years old, otherwise fit, active, and working full-time with no major health conditions—that makes the standard research findings more or less directly applicable to me? 3. What don't we know yet about my tumor or my health that could change this decision or alter my outlook later? 4. When we discuss numbers regarding cure rates, recurrence, or risks like incontinence and sexual dysfunction, where do those statistics come from—are they based on this clinic's own patient outcomes, national averages, or study groups that might look different from me? 5. Has my case already been discussed in a multidisciplinary meeting that includes both urologic surgeons and radiation oncologists? 6. If I were to consult a radiation oncologist or get a second opinion at a different center, would they likely interpret the evidence differently or suggest a different primary approach for my age and risk group?
Patient's own values elicitation, then matching each option against those stated values
### Domain 5: Fit With What Matters to Me #### Self-Directed Reflective Questions (Asking Yourself What Matters Most) 1. What matters most to me right now—living as long as possible, maintaining my current active lifestyle and full-time work, or preserving baseline physical functions like urinary continence and sexual health? 2. Given that I am currently fit, healthy, and working full-time, what outcome or side effect would I be most afraid of losing if a treatment goes badly? 3. Is there a line I would not want crossed—such as experiencing permanent urinary leakage, long-term erectile dysfunction, or taking short-course hormone therapy that impacts my energy and work—regardless of the medical benefit? 4. Whose voice, if anyone—such as a partner, family member, or trusted friend—do I want in this decision with me, and how much influence should their concerns have on my choice? 5. Given that I have been told I need to decide "within the next few weeks," am I taking enough time to truly understand my own priorities, or am I letting urgency push me into a decision? --- #### Connecting My Values to the Specific Options 6. Given that staying physically active and continuing to work full-time matter deeply to me, which of these options—radical prostatectomy, external-beam radiation with short-course hormone therapy, or active surveillance—is actually built around supporting that lifestyle, and which one isn't? 7. While surgery or radiation with hormone therapy may both technically work clinically for intermediate-risk prostate cancer (Gleason 3+4, PSA 7.2), does one of them carry recovery demands or side effects that simply do not fit how I want to live my daily life? 8. Did anyone on my care team ask me what matters most to me—my work, my active routine, or my functional priorities—before recommending surgery and radiation, or was active surveillance set aside without knowing my personal preferences?
Time, cost, and burden of each option; support and preparation needed to actually carry it out
**Domain 6: Practical & Logistical Reality** *Note: Specific financial figures, insurance coverage details, and home care arrangements were not provided in the case data; the questions below are designed to gather that missing information.* 1. How many total appointments, hospital stays, or daily visits will be required for radical prostatectomy versus external-beam radiation with short-course hormone therapy, and how does that compare to the schedule for active surveillance? 2. Given that I work full-time and lead an active life, how much time off work will I need to take for surgery and its recovery compared to daily radiation sessions and hormone therapy? 3. How long is the typical physical recovery time after surgery before I can safely return to my normal work duties and physical activities? 4. What are the expected out-of-pocket costs for each option—including surgery, radiation treatments, hormone medications, and ongoing testing—and who in the office can help me verify what my insurance covers? 5. Will I need a caregiver or family member to take time off work or alter their schedule to drive me to appointments or assist me at home after surgery or during radiation, and for how many days or weeks? 6. How will undergoing treatment affect my ability to manage my current work and personal responsibilities while I am recovering or receiving daily radiation? 7. What specific supplies, equipment (such as urinary catheter care items), or setup changes will I need to prepare at home before undergoing surgery or starting radiation? 8. If I experience urgent side effects, urinary problems, or complications after hours or after being discharged, who specifically should I call, and how do I reach them? 9. Are there patient navigators, official decision aids, or support resources available through this clinic to help me process these options? 10. Since I have been given a timeframe of a few weeks to decide, can we schedule a follow-up conversation after I have had time to review these details and discuss them with my support system?
How locked-in each option is, the real deadline, and what happens step by step after deciding
1. If I start one of these options—such as external-beam radiotherapy with short-course hormone therapy, surgery, or active surveillance—can I stop or change course later if it isn't right for me? 2. Is choosing surgery or radiation a permanent decision, or can other treatment options be revisited if my prostate cancer comes back in the future? 3. If I choose to wait or pursue active surveillance for now, does that decision close off the option to have surgery or radiation later on? 4. I was told a decision needs to be made within the next few weeks—what is the actual medical deadline for making my choice, and what are the risks if I take a little extra time to decide? 5. Once I decide between a radical prostatectomy, radiation with short-course hormone therapy, or active surveillance, what happens next, step by step? 6. How and when will we test my PSA or run other checks to know if the option I chose is working? 7. Who do I tell if I change my mind about my treatment choice before it starts, and how much notice do you need to adjust the plan? 8. Can I get a written or recorded summary of this discussion and my options so I don't have to rely on memory alone?
Here is the consolidated, prioritized Patient Question Set organized in the natural sequence of a clinical consultation. ### Consolidated Patient Question Set | # | Domain | Question (first-person, plain language) | Why this question matters | | :--- | :--- | :--- | :--- | | **1** | Domain 1: The Decision Itself | My urology
Here are the three most critical questions for the patient to ask, distilled from all seven domains, along with the rationale for their selection and what a complete answer should sound like. --- ### Question 1: Unpacking Active Surveillance * **(a) Plain First-Person Question:** "Active surveillance was mentioned briefly, but given my specific biopsy results of Gleason 3+4 and PSA of 7.2, is close monitoring actually a safe and reasonable option for me right now, or is there a clear medical reason why I need active treatment immediately?" * **(b) Why It Was Chosen:** Active surveillance was only raised in passing during initial consultations, leaving a major potential option unexplored. Before committing to major surgery or radiation with hormone therapy, the patient must know if immediate intervention is medically mandatory or if monitoring is a safe, guideline-supported path for his specific intermediate-risk profile. * **(c) What a Good Answer Sounds Like:** The clinician should directly address how his specific tumor characteristics (Gleason 3+4, PSA 7.2, localized) fit into current clinical guidelines for surveillance versus active treatment. A complete answer will explain the potential risk of cancer progression under surveillance, outline what a monitoring protocol would involve (e.g., repeat PSA tests, MRIs, repeat biopsies), and explain clearly why surveillance is or is not recommended in his case, rather than dismissing it without explanation. --- ### Question 2: Comparing Life-Impact Trade-Offs * **(a) Plain First-Person Question:** "When comparing radical prostatectomy against radiation combined with short-course hormone therapy, what are the specific long-term differences in side effects—especially regarding urinary leakage, sexual function, fatigue, and my ability to keep working full-time and staying physically active?" * **(b) Why It Was Chosen:** The patient is 58, fit, active, and working full-time, but his medical team has not yet documented or explored his personal functional priorities. Surgery and radiation plus hormone therapy have fundamentally different side-effect profiles, recovery timelines, and long-term impacts on urinary, sexual, and energy levels. He needs a direct comparison to weigh these trade-offs against his lifestyle. * **(c) What a Good Answer Sounds Like:** The clinician should provide specific, comparative likelihoods (or ranges) for major long-term side effects for both options—specifically addressing urinary incontinence, erectile dysfunction, radiation bowel changes, and hormone-therapy side effects like fatigue or loss of muscle mass. A complete answer will also give realistic recovery timelines for returning to full-time work and physical activity for both surgical recovery and the radiation/hormone regimen. --- ### Question 3: Clarifying Urgency and Deliberation Time * **(a) Plain First-Person Question:** "I was told I need to make a decision
**Not found in the case data:** * **Documented patient values and priorities:** No record of the patient's preferences regarding functional outcomes (urinary continence, sexual function), lifestyle impact, risk tolerance, or preferences regarding hospital visits versus active intervention. * **Detailed evaluation of active surveillance:** Active surveillance was only mentioned in passing by urology, without specific discussion of whether it is safe, appropriate, or structured for this patient's Gleason 3+4, PSA 7.2 disease. * **Quantitative benefit and harm estimates:** No numerical estimates or statistical probabilities provided for cancer-specific survival, recurrence rates, or specific side effect risks (e.g., long-term incontinence, erectile dysfunction, bowel toxicity) for surgery versus radiation plus hormone therapy versus surveillance. * **Multidisciplinary input:** No record of consultation with a radiation oncologist or evaluation by a multidisciplinary tumor board; options have only been presented by urology. * **Logistical and treatment specifics:** No details regarding the specific length/duration of radiotherapy (number of fractions/weeks), the specific regimen or duration of short-course hormone therapy, precise time off work required for recovery, or financial/insurance details.
### Closing Reflection
1. **[Remember]**
A question that learners often overlook before completing this exercise is **Lens 4, Question 5**: *"Has my case already been discussed in a multidisciplinary meeting that includes both urologic surgeons and radiation oncologists?"* Most patients assume that seeing one specialist means all specialists have systematically collaborated on their case. Asking this question uncovers whether the options presented reflect a consensus among experts or simply the individual perspective of the first specialty clinic visited.
2. **[Analyse]**
The original clinical scenario was framed as a constrained choice rather than an open, preference-sensitive decision. While two active modalities (surgery and radiation with hormone therapy) were presented as a choice, active surveillance was minimized ("mentioned once in passing"), an artificial urgency was introduced ("within the next few weeks"), and the clinical team had not documented or explored what mattered most to the patient regarding functional trade-offs, work, and lifestyle. This signal reveals a decision that was being pushed toward rapid active intervention rather than one structured around patient-centered deliberation.
3. **[Evaluate]**
If this patient walks into the consult equipped with these questions, the single biggest improvement to their outcome will be the prevention of **value-mismatched treatment and permanent decisional regret**. Instead of being driven by unexamined urgency into an irreversible active treatment that might severely disrupt his active lifestyle and full-time work, these questions force the clinical team to slow down, explain the true safe window for decision-making, thoroughly evaluate active surveillance, and explicitly weigh functional trade-offs (continence, potency, fatigue) directly against his personal daily priorities.
***
*Generating rigorous, highly tailored first-person questions on someone else’s behalf—without pushing an agenda or putting words in their mouth—is one of the hardest and most protective patient advocacy skills in medicine. You have built a framework that protects this patient's autonomy while ensuring his care team addresses what truly matters to him.*